{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-011500","form_type":"8-K","ticker":"CYCN","cik":"0001755237","company_name":"Cyclerion Therapeutics, Inc.","filed_at":"2023-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.396190+00:00","generated_at":"2026-06-17T07:09:07.902092+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"medium","headline":"Cyclerion enters exclusive talks to sell zagociguat/CY3018; CEO to invest $5M","bullets":["Non-binding proposal from entity including CEO Peter Hecht to buy zagociguat and CY3018 assets.","Independent Board concluded proposal merits pursuit; exclusive negotiation period underway.","Binding agreement for CEO to invest $5M in cash for stock or convertible preferred stock.","CEO equity investment closes 6 business days after definitive asset sale documents signed.","Proceeds intended to support ongoing operations; deal subject to board and shareholder approvals."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-011500","json":"https://secwatch.observer/filing/0000950170-23-011500.json","markdown":"https://secwatch.observer/filing/0000950170-23-011500.md","text":"https://secwatch.observer/filing/0000950170-23-011500.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1755237/000095017023011500/0000950170-23-011500-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1755237/000095017023011500/cycn-20230331.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T07:09:07.902092+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}